Target intelligence / Profile preview

Intestinal motility regulatory network

Molecular classification
Other
01

Overview

The intestinal motility regulatory network is a multi-component physiological system that governs the mechanical processing and transit of luminal contents (Furness, 2012, Journal of Internal Medicine). It consists of the enteric nervous system (ENS), often referred to as the 'second brain,' the interstitial cells of Cajal (ICC) acting as electrical pacemakers, and the gastrointestinal smooth muscle layers (Sanders et al., 2014, Nature Reviews Gastroenterology & Hepatology). This network integrates intrinsic sensory information with extrinsic autonomic input to coordinate complex motor patterns such as peristalsis and the migrating motor complex (Gershon, 2013, Journal of Clinical Investigation). Clinical manifestations of network failure include gastroparesis, chronic idiopathic constipation, and irritable bowel syndrome (Camilleri, 2012, NEJM). Pharmacological intervention typically targets specific molecular nodes within this network, such as 5-HT4 receptors to accelerate transit or mu-opioid receptors to slow it, rather than the network as a single entity (Ford et al., 2014, American Journal of Gastroenterology). Because this term describes a broad physiological system rather than a single therapeutic molecule, it is classified as a network rather than a discrete drug target.

Other names
Enteric nervous systemGastrointestinal motility complexMyenteric plexusInterstitial cells of Cajal networkENS-ICC-smooth muscle unit
02

Mechanism of action

Modulation of enteric neurotransmission and pacemaker activity via specific receptors (e.g., 5-HT4, Mu-opioid, D2) or ion channels to alter gastrointestinal transit time and contractile patterns (Camilleri, 2012, NEJM).

03

Biological functions

PeristalsisSegmentationGastric emptyingMigrating motor complexIntestinal transit
04

Disease associations

Irritable bowel syndromeChronic idiopathic constipationGastroparesisPostoperative ileusHirschsprung diseaseOgilvie syndrome
05

Safety considerations

QT prolongation and cardiac arrhythmias (associated with older prokinetics like Cisapride)Tardive dyskinesia (associated with long-term Metoclopramide use)Ischemic colitis (associated with Alosetron)Severe diarrhea and electrolyte imbalanceDependency or rebound effects
06

Interacting drugs

Prucalopride

7 more in the full profile.

07

Biomarkers

Gastric emptying scintigraphyColonic transit time (radiopaque markers)Wireless motility capsule (SmartPill)Anorectal manometryBreath testing (for gastric emptying)

Beyond the preview

Go deeper on Intestinal motility regulatory network.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal motility regulatory network.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call